



US007741302B2

(12) **United States Patent**
Kawakami

(10) **Patent No.:** **US 7,741,302 B2**

(45) **Date of Patent:** **Jun. 22, 2010**

(54) **TRANSPOSASE AND METHOD OF GENE MODIFICATION**

(75) Inventor: **Koichi Kawakami**, Chiba (JP)

(73) Assignee: **Japan Science and Technology Agency**, Saitama (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **11/376,264**

(22) Filed: **Mar. 14, 2006**

(65) **Prior Publication Data**

US 2006/0212959 A1 Sep. 21, 2006

Related U.S. Application Data

(62) Division of application No. 10/148,639, filed as application No. PCT/JP00/08014 on Nov. 14, 2000, now Pat. No. 7,034,115.

(30) **Foreign Application Priority Data**

Dec. 3, 1999 (JP) 11-345508

Apr. 11, 2000 (JP) 2000-109033

(51) **Int. Cl.**

A01N 43/04 (2006.01)

A01N 37/18 (2006.01)

C07K 1/00 (2006.01)

C07H 21/02 (2006.01)

C12N 15/63 (2006.01)

(52) **U.S. Cl.** **514/44**; 514/2; 536/23.1; 530/350; 435/320.1; 435/455

(58) **Field of Classification Search** 514/44, 514/2; 536/23.1; 530/350; 435/455, 320.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,034,115 B1 4/2006 Kawakami

2006/0211116 A1 9/2006 Kawakami

2006/0212958 A1 9/2006 Kawakami

OTHER PUBLICATIONS

Kawakami et al., Nov. 1999, GenEmbl Accession No. AB032244, pp. 1-3.*

SPTREMBL Accession Nos. Q98968, 98969, 98970, and 98971, 1997, pp. 3-4.*

Ivics et al., 1997, Cell, vol. 91, p. 501-510.*

Kawakami et al., 2000, UniProt, Accession No. Q9PVN3, computer printout, p. 2-3.*

Atkinson et al., 1993, PNAS, vol. 90, pp. 9693-9697.*

K. Kawakami et al., *Gene*, 240: 239-244 (1999).

K. Kawakami et al., *Gene*, 225: 17-22 (1998).

A. Koga et al., *Genbank*, Acc. No. D84375 (1999).

A. Koga et al., *FEBS Letters*, 461: 295-298 (1999).

A. Koga et al., *Nature*, 383: 30 (1996).

G. Luo, *Proc. Natl. Acad. Sci. USA*, 95: 10769-10773 (1998).

L. Zhang et al., *Nucleic Acids Research*, 26 (16): 3687-3693 (1998).

A. Sherman et al, *Nature Biotechnology*, 16:1050-1053 (1998).

Z. Li et al., *Somatic Cell and Molecular Genetics*, 24(6): 363-369 (1998).

E. Rubin et al, *Proc. Natl. Acad. Sci USA*, 96: 1645-1650 (1999).

K. Kawakami et al., *Gene*, 240: 239-244 (1999), Database accession No. AB032244 (abstract only).

A. Koga et al., *Nature*, 383: 30-30 (1996), Database accession No. Q98969 (abstract only).

Izsvak et al., *Biochemistry & Cell Biology*, 75: 507-523 (1997).

GenEmbl Accession No. AB032244, Nov. 26, 1999, pp. 1-3.

SPTREMBL Accession Nos. Q98968, 98969, 98970, 98971, 1997, pp. 3-4.

Rudinger, 1976, Peptide Hormones, Parsons, University Park Press, Baltimore. p. 1-7.

Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.

Skolnick et al., 2000, Trends in Biotech, vol. 18, pp. 34-39.

De Lorenzo, Victor, "Genetic Engineering Strategies for Environmental Applications," Current Opinion in Biotechnology, 3(3): 227-231 (1992).

Lewin, B., "Genes VI", Chapter 18, p. 564 (Oxford University Press 1997) (excerpt).

Lander, E.S., et al., "Initial sequencing and analysis of the human genome", Nature, 409(6822):860-921 (2001) (excerpt).

Ivics, Z., et al., "Molecular Reconstruction of Sleeping Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells", Cell, vol. 91, 501-510 (1997) (excerpt).

Kunze et al., "Transcription of transposable element *Activator (Ac)* of *Zea mays* L.," The EMBO Journal, vol. 6, No. 6, pp. 1555-1563 (1987).

Izsvak et al., "Short Inverted-Repeat Transposable Elements in Teleost Fish and Implications for a Mechanism of Their Amplification," Journal of Molecular Evolution, vol. 48, pp. 13-21, (Jan. 1999).

* cited by examiner

Primary Examiner—Shin-Lin Chen

(74) *Attorney, Agent, or Firm*—Edwards Angell Palmer & Dodge LLP; Peter F. Corless; Mark D. Russett

(57) **ABSTRACT**

A transposase encoded by the Tol2 element; a polynucleotide encoding the same; a method of modifying the gene structure of a cell (preferably a vertebrate cell) by using the above protein; a method of modifying the function of a cell by modifying the gene structure thereof; and a cell having been modified in function by these methods. Also the structure of a cis element necessary in gene transfer is clarified and presented.

5 Claims, 5 Drawing Sheets

FIG. 1




FIG. 2

To12 : 106 VDSVFPVKHVPVTVNKAILRYIIQGLHPFSTVDLPSFKELISTLQPGISVITRPTLRSK 165
 ++ + P K+ V++ K L II +PF+ V+ F E + +L+P + +R T R

Ac : 215 INLIEPYKYDEWVSLKLLHLA--IIMHEYPFNIVEHEYFVEFVKSLRPHFPIKSRVTARKY 273

To12 : 166 IAEAALIMKQKVTAAMSEVE--WIAITTTDCWTA--RRKSFIGVTAHWINPG--SLEHSAALA 222
 I + L K+K+ + +V+ +TT/ D WT+ + KS++ VT HWI+ L++

Ac : 274 IMDLYLEEKEKLYGKLDVQSRFSIDMDMWTSCQNKSYMCVTIHWIDDDWCLQKRIVGFF 333

To12 : 223 CKRLMGSHTEFLASAMNDIHSEYEIRDKVVCITTTDSSGNSFMKAFRVFGVENNDIETEAR 282
 + G HT + L+ I ++ I K+ + D+ S N++

Ac : 334 --HVEGRHTGQRLSQTFTAIMVKWNIEKKLFALSLDNAS-----ANEVAVHDI 379

To12 : 283 RCESDDTDSEGGEGSDGVEFQDASRVLDQDDGFEFQLPKHQKACACHLLNLVS 335
 + OTDS DG F H +CACH+LNLV+

Ac : 380 IEDLQDTSNLV---CDGAFF-----HVRGACHILNLVA 410

FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

A GTTTTTTTTTTACATCTCAACTG-Tol2-CTCAACTGATAGTCTAATCACAC
 B CGCTGAGCTCTCTTATATAGAGA-Tol2-TATAGAGATGGCTGTTATACGAG
 C AAGTGACGTCAATGTGTTTCAG-Tol2-GTTTTTCAGCTCATCTGTTTCATTA

TRANSPOSASE AND METHOD OF GENE MODIFICATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. Application Ser. No. 10/148,639, filed Jun. 3, 2002, now U.S. Pat. No. 7,034,115 which is a U.S. national phase application under 35 U.S.C. §371 of International Application Serial No. PCT/JP00/08014, filed Nov. 14, 2000, which claims the benefit of Japanese Application Serial No. 2000-109033, filed Apr. 11, 2000, and Japanese Application Serial No. 11-345508/1999, filed Dec. 3, 1999. The entire contents of all of the above-referenced applications are incorporated herein by this reference.

TECHNICAL FIELD

The present invention relates to a new protein having a transposase-like activity, a transposase composed of the above protein, a method of modifying the gene structure of a cellular gene by using these protein and transposase, a method of modifying the function of a cell by this method, a method of introducing a gene by this method, a plasmid used for this method, and a cell having been modified in function by this method.

BACKGROUND ART

The medaka fish (*Oryzias latipes*) is a teleost inhabiting in East Asia and has been used for studying vertebrate genetics. The mutations at the *i* locus of the medaka fish cause amelanotic skin and red-colored eyes. This *i* locus is known to encode a gene for tyrosinase. From one of the *i* alleles, *i*⁴, DNA of about 4.7-kb was cloned and found to have a transposon-like sequence; that is to say, it included open reading frames homologous to transposases of transposons of the hAT family including hobo of *Drosophila*, Ac of maize and Tam3 of snapdragon, and short terminal inverted repeats. This medaka element was named Tol2. The laboratory strains of the medaka fish contain about 10 copies of this element per haploid genome.

In the *i*⁴ mutant fish, the Tol2 element found in the tyrosinase gene locus has been shown by PCR to be excised from the target locus during embryonic development (Koga et al., 1996).

Zebrafish (*Danio rerio*), as well as the medaka fish (*Oryzias latipes*), is a small teleost and has been developed as a model animal to study vertebrate genetics and development (Takeuchi, 1966; Yamamoto, 1967; Streisinger et al., 1981). In zebrafish, large-scale chemical mutagenesis screens have been performed (Driever et al., 1996; Haffter et al., 1996), and, to facilitate cloning of the mutated genes, an insertional mutagenesis method using a pseudotyped retrovirus has been developed and performed (Lin et al., 1994; Gaiano et al., 1996; Amsterdam et al., 1997). Also, in an attempt to develop transposon technologies that would allow enhancer trap and gene trap screens to be performed, transposition of transposons of the Tc1/mariner family in fish has been tested and demonstrated (Ivics et al., 1997; Raz et al., 1997; Fadool et al., 1998). Although these results are encouraging, neither highly efficient transgenesis nor insertional mutagenesis methods using a transposon have not yet been developed.

The present inventors have been interested in developing novel transposon technologies using the Tol2 element. As a first step towards this goal, the present inventors developed a

transient embryonic excision assay using zebrafish embryos, in which zebrafish fertilized eggs were injected with a plasmid DNA harboring the Tol2 element, showed that the Tol2 element was excisable from the injected plasmid DNA, and indicated that the Tol2 element is an autonomous member and is active in zebrafish (Kawakami et al., (1998) Gene 225, 17-22). Although the DNA sequence of the Tol2 element is similar to those of transposases of transposons of the hAT family, neither an active enzyme, which can function in trans, nor cis-elements essential for the excision reaction have been identified. In order to develop the Tol2 element as a useful tool for transgenesis and insertional mutagenesis, it is necessary to dissect and characterize cis and trans requirements. The functional transposase encoded by the Tol2 element had not yet been identified prior to the present invention.

DISCLOSURE OF THE INVENTION

The present invention first aims to identify mRNA transcribed from the Tol2 element injected in zebrafish embryos. Secondly, in order to determine whether the transcript encodes an active enzyme or not, the present invention develops a novel assay method, in which zebrafish fertilized eggs are co-injected with RNA synthesized in vitro using the Tol2 cDNA as a template and a plasmid DNA harboring a nonautonomous Tol2 element, which has a deletion in the transposase coding region.

The present invention also identifies the active trans-factor and essential cis-elements, that function in excision of the Tol2 element in zebrafish.

Consequently, the present invention results in a new protein encoded by the Tol2 element and a polynucleotide encoding the same. Also the present invention, by using the above protein, results in a method of modifying the gene structure of a cell, preferably the gene structure of a vertebrate, in a method of modifying the function of a cell by modifying the gene structure thereof, and in a cell having been modified in function by these methods. Furthermore, the present invention discloses the cis-element structures essential for transposition, and presents the same.

The present invention relates to a protein having the transposase-like activity, which has an amino acid sequence shown in SEQ ID NO:2, an optionally substituted amino acid sequence with any replacements or deletions in part of the original amino acid sequence, or an optionally substituted amino acid sequence with addition of other amino acids to the original amino acid sequence. Also the present invention relates to a transposase comprising the said protein.

Further, the present invention relates to the nucleic acid encoding the said protein, wherein the nucleic acid is preferably DNA having a nucleotide sequence shown in SEQ ID NO:1 or DNA which can hybridize to the said DNA, or is the corresponding RNA.

The present invention reveals that the said protein has a transposase-like activity which catalyzes transposition of the above transposon, and relates to a method of modifying the gene structure comprises the excision in part of a gene in a cell, preferably a vertebrate cell, or the insertion of the excised part into any other locus in the presence of the said protein or the nucleic acid which can produce the said protein. It is preferable that the said excised gene has nucleotide sequences containing at least one inverted repeat (the Angel elements) in forepart of its nucleotide sequence.

Further, the present invention relates to a method of inserting a foreign gene into a gene of a cell, and a method of

modifying a function of a cell based on gene expression, and furthermore relates to a cell having been modified in function by the said method.

Also, the present invention relates to a plasmid used in these methods and, more in detail, a plasmid which contains DNA having a nucleotide sequence that includes at least one inverted repeat sequence in the forepart of its nucleotide sequence.

Furthermore, in a method of inserting any DNA into the genomic DNA of a vertebrate, the present invention relates to a method of inserting any DNA into the genomic DNA of a vertebrate which is characterized by operating the said insertion of DNA autonomously using the transposase activity, wherein a preferable DNA is the Tol2 element and the vertebrate is fish.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the structure of the Tol2 plasmid and the transcript, and the structure of cDNAs described in the present invention. The dotted lines indicate introns. The inverted repeat (the Angel elements) in the first intron and positions of primers used in the present invention are shown by arrows.

FIG. 2 shows a comparison of amino acid sequences of transposases of the Tol2 element described in the present invention (residues 106-335 of SEQ ID NO:2) and the Ac element (SEQ ID NO:3).

FIG. 3 shows a scheme for the transient embryonic excision assay by co-injection described in the present invention. Primers (tyr-ex4f and tyr-ex5r) used to detect the excision products are shown by arrows.

FIG. 4 shows photos, substitutes for drawings, which show the results of the PCR analysis of the excision reaction in zebrafish embryos described in the present invention (SEQ ID NOs:4-9, respectively in order of appearance).

FIG. 5 shows the structures of the (Tol2-tyr) Δ RV plasmid used for transposition of the Tol2 element into the genome, the Tol2-tyr plasmid and Tol2 cDNA. The black line in the upper part of FIG. 5 shows the probe used for Southern blot analysis.

FIG. 6 shows photos, substitutes for drawings, which show the results of Southern blot analysis of F1 progeny fish from each parental fish (ff-1 and ff-7), wherein the presence of Tol2 is identified (FIG. 6, A) and show the results of PCR (FIG. 6, B).

FIG. 7 shows the nucleotide sequences surrounding the Tol2 element inserted in the genome of F1 progeny A (left: SEQ ID NO:10; right: SEQ ID NO:11), B (left: SEQ ID NO:12; right: SEQ ID NO:13) and C (left: SEQ ID NO:14; right: SEQ ID NO:15) from ff-7.

BEST MODE FOR CARRYING OUT THE INVENTION

Previously, the present inventors injected the Tol2-tyr plasmid, a plasmid harboring the Tol2 element cloned from the tyrosinase gene locus, into zebrafish fertilized eggs and showed that the Tol2 element is excisable from the injected plasmid DNA (Kawakami et al., 1998). In order to identify a transcript encoding a putative transposase activity, total RNA from embryos injected with the Tol2-tyr plasmid were prepared. The present inventors first performed 3' RACE using four pairs of nested primers that annealed different parts of the Tol2 sequence.

Nested forward primers used to perform 3' RACE are:

To12f2;
5' -TTGGTCAGACATGTTTCATTG-3' (SEQ ID NO:16)
and

To12f3;
5' -ATGTTTCATTGGTCCTTTGGA-3', (SEQ ID NO:17)

To12f4;
5' -ATAGCTGAAGCTGCTCTGATC-3' (SEQ ID NO:18)
and

To12f5;
5' -CTGCTCTGATC ATGAAACAG-3', (SEQ ID NO:19)

To12f8;
5' -GCTTAATAAAGAAATATCGGCC-3' (SEQ ID NO:20)
and

To12f9;
5' -AATATCGGCCCTTCAAAAGTTCG-3', (SEQ ID NO:21)
and

To12f12;
5' -CTGTAATCAGAGAGTGTATGTGTA-3' (SEQ ID NO:22)
and

To12f13;
5' -ATTGTTACATTATGCATACAAT-3'. (SEQ ID NO:23)

cDNAs with polyadenylation were successfully amplified by 3' RACE using Tol2f8 and Tol2f9, and Tol2f4 and Tol2f5, but not by 3' RACE using Tol2f2 and Tol2f3, and Tol2f12 and Tol2f13.

Then, using nested reverse primers designed to perform 5' RACE,

To12r4; 5' -CTCAATATGCTTCCTTAGG-3' (SEQ ID NO:24)
and

To12r5; 5' -CTTCCTTAGGTTTGATGGCG-3', (SEQ ID NO:25)

5' RACE was performed and the full-length Tol2 transcript of 2156 nucleotides was identified (FIG. 1).

The cDNA sequence obtained is shown in SEQ ID NO:1.

FIG. 1 shows the structures of the Tol2 plasmids and its transcript. The top line of FIG. 1 shows the full-length Tol2 (Tol2-tyr). Dotted lines in the figure show introns. The inverted repeat (the Angel elements) in the first intron and positions of the said primers are shown by arrows. The lower three lines of FIG. 1 show the results of 3' RACE and 5' RACE. In each case, introns are shown as dotted lines.

The fifth line shows the structure of the full-length mRNA. The translated region corresponds to the nucleotide sequence between the 85th (ATG) and the 2032nd nucleotide (TAG) of cDNA of sequence number 1.

The two lines in the bottom show the structures of deletion mutants, (Tol2-tyr) Δ RV, and (Tol2-tyr) Δ in1 Δ RV.

In the 5' RACE analysis, aberrant transcripts that started from the plasmid sequence and jumped into cryptic splice acceptor sites in the first exon of the Tol2 element were also found (data not shown). These transcripts were not studied further.

DNA sequencing of the cDNA revealed the exon-intron structure of the Tol2 element (i.e., four exons and three introns) (as shown in the upper part of FIG. 1). The cDNA encodes a protein of 649 amino acids. The amino acid sequence of this protein is shown in SEQ ID NO:2.

Although the Tol2 element had been known to have a transposon-like sequence, the present invention for the first time identified that the Tol2 element encodes a protein and the

expression of the protein described here generates the function. That is to say, the present invention results in a new protein encoded by the Tol2 element and also a polynucleotide which encodes the protein described here.

FIG. 2 shows a comparison of amino acid sequences of the protein described in the present invention and a known transposase of a transposon of the hAT family. This comparison shows these proteins are similar, especially in the middle part (FIG. 2). But the amino acid sequences of NH₂— and COOH-terminus rather varies.

In order to determine whether the protein (the Tol2 transcript) identified in the present invention encodes a functional enzyme, a new transient embryonic excision assay by co-injection was developed and, by using this method, identification of the enzymatic activity was performed.

Zebrafish fertilized eggs were co-injected with mRNA synthesized in vitro using the cDNA shown in the sequence number 1 as a template and the (Tol2-tyr)ΔRV plasmid containing (Tol2-tyr)ΔRV (see FIG. 1), which has a deletion of the nucleotides between the EcoRV sites of the Tol2 element. About 8 hours after the co-injection, DNA was prepared from each embryo and analyzed by PCR using primers, tyr-ex4 f and tyr-ex5r,

tyr-ex4f:
5'-GCTACTACATGGTGCCATTCT-3' (SEQ ID NO:26)

tyr-ex5r:
5'-CACTGCCAGATCTGCTGGCTT-3' (SEQ ID NO:27)

which were prepared based on the sequence adjacent to the Tol2 element. FIG. 3 shows a scheme of this method and these primers are shown in FIG. 4A.

PCR products of about 250 bp, indicative of excision of the Tol2 element from (Tol2-tyr)ΔRV plasmid, was amplified in all embryos analyzed (56 out of 56, see FIG. 4B lanes 1-10). This PCR product was never detected from embryos injected only with the (Tol2-tyr)ΔRV plasmid DNA (0 out of more than 50, see FIG. 4B lanes 11-20).

The PCR products from six different embryos were cloned and sequenced. Three of them had the wild-type medaka fish tyrosinase gene sequence (FIG. 4C, excision product a), indicating that precise excision had occurred, and the other three had nearly wild type sequences with addition of a few nucleotides (FIG. 4C, excision products b and c), characteristic to excision of transposons of the hAT family (Pohlman et al., 1984; Sutton et al., 1984; Koga et al., 1996; Kawakami et al., 1998), suggesting that the excision event in this experiment is catalyzed by a transposase-like activity.

These results, i.e., when co-injected with the mRNA which has the nucleotide sequence shown in sequence number 1 of the present invention, the PCR product characteristic to excision of the transposon was obtained and, when co-injected without the mRNA, such PCR products were not obtained, indicate that the protein (the Tol2 transcript) described in the present invention encodes a functional transposase, which can catalyze the excision. Further, these results show that the (Tol2-tyr)ΔRV plasmid contains sequences of cis-elements essential for the excision.

FIG. 4 shows the results of this experiment and arrows in FIG. 4A show positions and directions of the primers used in the analyses. The upper panel of FIG. 4B is a photo, a substitute for a drawing, which shows the PCR products using primers tyr-ex4f and tyr-ex5r, and the lower panel shows the PCR products using primers Tol2f1 and Tol2r3. In lanes 1-10, zebrafish embryos were injected with both the (Tol2-tyr)ΔRV

plasmid and the Tol2 mRNA, in lanes 11-20 the (Tol2-tyr)ΔRV plasmid alone was injected, and in lane G and P PCR products were amplified from 50 ng of the zebrafish genomic DNA and from 10 pg of the (Tol2-tyr)ΔRV plasmid DNA.

FIG. 4C shows the DNA sequences of the excision products obtained in the above experiments. The Tol2 sequence is shown in bold and 8 bp direct repeat sequences flanking to the Tol2 element are underlined.

It was noted that, although the excision products could be detected after a single-round PCR amplification in the experiments in the present invention, two rounds of PCR were required in the previous analysis, in which fertilized eggs were injected with a sole plasmid DNA containing the full-length Tol2 element without mRNA prepared in vitro. The higher efficiencies of the excision reaction observed here can be explained as more transposases were supplied by RNA injection than those supplied by DNA injection.

The first intron of the Tol2 element contains about 300 bp of large inverted repeats, and the repeat was recently identified as the Angel element (Izsvak et al., 1999) (see FIG. 1). To test whether the sequence in the intron is essential for excision, we constructed the (Tol2-tyr) Δin1ΔRV plasmid, containing (Tol2-tyr) Δin1ΔRV (see the bottom of FIG. 1), which completely lacked the sequences of the first intron, and its activity was analyzed by co-injection with the Tol2 mRNA as the said method. This result is shown in FIG. 4D.

The upper panel of FIG. 4D is a photo, a substitute for a drawing, which shows PCR products amplified using primers tyr-ex4f and tyr-ex5r and, the lower panel shows PCR products amplified using primers Tol2f1 and Tol2r3. In lanes 1-8, zebrafish embryos were injected with both the (Tol2-tyr) Δin1ΔRV plasmid and the Tol2 mRNA, in lanes 9-12 both the (Tol2-tyr)ΔRV plasmid and the Tol2 mRNA were injected, and, in lanes 13-16, the (Tol2-tyr) Δin1ΔRV plasmid alone was injected. Lane P shows the PCR product amplified from 10 pg of the (Tol2-tyr) Δin1ΔRV plasmid DNA.

In lanes 9-12, the said experiment was conducted as controls and the PCR products indicating the excision could be detected, but the excision product could not be detected in lanes 1-8 when the plasmid lacking the intron part (0 out of 16, see FIG. 4D lanes 1-8) was used, suggesting that the first intron contains cis-elements essential for excision.

Further, the (Tol2-tyr) Δin1 plasmid, containing (Tol2-tyr) Δin1 which restored the ΔRV deletion and was about the same size as the (Tol2-tyr) ΔRV plasmid, i.e., which has a deletion between the 644th and 2163rd nucleotides of the Tol2 element, was also examined by the co-injection assay, but PCR product indicating the excision could not be obtained (0 out of 16, data not shown).

Although, further analyses using smaller deletions and point mutations in the first intron sequence will be needed to define the essential cis-sequences for excision precisely, since these results show that the intron part is essential for the excision and the intron contains the Angel elements as inverted repeats, it can be thought that the inverted repeats are essential sequences for the excision described in the present invention.

Thus, we successfully identified for the first time the transcript (the protein described in the present invention) encoded by the Tol2 element and also identified a transposase activity of this protein and cis-sequences essential for transposition. These discoveries will lead to a biochemical characterization of the Tol2 transposase.

On the other hand, transposition of transposons belonging to the Tc1/mariner family into the zebrafish genome has been reported (Raz et al., 1997; Fadool et al., 1998). In the experiments described in their reports, zebrafish one-cell-stage

embryos were co-injected with transposase RNA transcribed in vitro and transposon vectors containing essential cis-sequences.

While a transposon belonging to a different family may have different specificities and efficiencies for insertion into the genome, by a method of present invention which is a novel transposon technology in fish using the Tol2 element, since its transposon excision procedure has been carried out in the way of Raz et al., it might be possible to transpose DNA such as the Tol2 element into the genome in the way conducted by using transposons of the Tc1/mariner family.

Therefore, we tested whether the Tol2 element can be inserted into the zebrafish genome by transposition. It is known that the zebrafish genome does not contain the Tol2 element.

To test whether the Tol2 element encodes a transposase that can catalyze transposition, zebrafish fertilized eggs were co-injected with RNA transcribed in vitro using the Tol2 cDNA as a template, which encoded a putative transposase, and a plasmid DNA harboring the (Tol2-tyr) Δ RV element, which has a deletion in part of the region presumed to code the transposase.

The structures of (Tol2-tyr) Δ RV plasmid and Tol2 cDNA are shown in FIG. 5. 3' and 5' indicate the direction of transcription.

The injected eggs were raised to adulthood and mated to non-injected fish. And the progeny fish were analyzed for the presence of the Tol2 sequence.

Two out of eight injected fish could transmit the Tol2 sequence to their progeny. These two fishes were named ff-1 (founder fish-1) and ff-7 (founder fish-7).

Two fish out of 68 F1 fish from the ff-1 fish had the Tol2 sequence. These two fish had the sequence of the plasmid portion as well as the Tol2 sequence. On the other hand, 25 fish out of 50 F1 fish from the ff-7 fish had the Tol2 sequence. These 25 fish did not have the plasmid sequence and were classified into three groups, A, B and C, from the result of Southern blot shown in FIG. 6A. 7 fish were grouped as A, 3 fish as B, and 15 fish as C.

FIG. 6A is a photo, a substitute for a drawing, which shows the result of Southern blot analysis using a probe shown in FIG. 5, in which DNA samples prepared from caudal fins of F1 fish from ff-1 and ff-7 were digested with EcoRV. Two samples from ff-1 showed the same pattern but samples from ff-7 showed three patterns, A, B and C.

Then, PCR analyses of F1 fish from ff-1 and ff-7 were performed. Primers used were shown in FIG. 5 as PCR1, PCR2 and PCR3. As controls, zebrafish genomic DNA (G) and genomic DNA plus (Tol2-tyr) Δ RV plasmid DNA (G+P) were used. In F1 fish from ff-7, PCR products using PCR2 and PCR3 could not be amplified. This indicated that progeny fish from ff-7, unlike progeny fish from ff-1, did not have the plasmid sequence flanking to the Tol2 element.

From the ff-7 progeny fish, DNA fragments containing the Tol2 sequence and the flanking region were cloned by inverse PCR and sequenced. In each three case, A, B and C, the Tol2 sequence was surrounded by zebrafish genomic sequences and 8 bp duplications were created adjacent to the insertion. 8 bp duplications at both ends of the Tol2 element are characteristic to integration of transposons of the hAT family, indicating that the integration described here was catalyzed by a transposase.

FIG. 7 shows the determined nucleotide sequences of three types, A, B and C. Tol2 in FIG. 7 shows the Tol2 sequence. In A repeats of [CTCAACTG], in B repeats of [TATAGAGA], and in C repeats of [GTTTTTCAG] were created at both ends of and adjacent to the Tol2 sequence.

In the vertebrate cultured cells and the germ line, transposition activities of Sleeping Beauty which was reconstituted and activated artificially (Ivics, Z., et al., Cell, 91, 501-510 (1977)), Tc3 of *C. elegans* (Raz, E., et al., Current Biology, 8, 82-88 (1977)) and mariner of *Drosophila* (Fadool, J. M., et al., Proc. Natl. Acad. Sci. USA, 95, 5182-5186(1988)), all belonging to the Tc1/mariner family, have been reported. No autonomous transposon activity residing endogenously in any vertebrate genome, however, has been reported.

The present invention is the first report that identified an autonomous element from a vertebrate genome and also for the first time reported a functional transposase activity in vertebrate.

Therefore, the present invention relates not only to a method to excise a gene autonomously in vertebrate but also to a method to insert the excised gene into any locus or any gene on the genome.

The protein in the present invention has the amino acid sequence shown in SEQ ID NO:2, but all of the amino acids shown there are not necessarily required, and the protein in the present invention can include a protein having the transposase activity described in the present invention or similar activities described above (both of these are called transposase-like activities) and also can include a protein having replacement or deletion in part of amino acids of the above protein, or having addition of any other amino acids to the above protein. And preferably it has the amino acid sequence derived from the Tol2 element. Further, the protein in the present invention includes a protein which is produced from mRNA having the nucleotide sequence corresponding to SEQ ID NO:1.

The nucleic acid in the present invention encodes the amino acid sequence which is related to the said protein, and preferably which has the polynucleotide having the sequence shown in SEQ ID NO:1. The nucleic acid in the present invention includes not only the said nucleotide sequence but also a nucleotide sequence which can hybridize to the said nucleic acid, preferably under stringent conditions.

As for a method of modifying the gene structure of a gene in a cell in the presence of the protein in the present invention or the nucleic acid which can produce the said protein, by introducing the protein or the nucleic acid, for instance the mRNA which can produce the protein described here, and, at the same time, by introducing genes including a gene to be transposed, for instance a plasmid, the gene structure in a cell can be modified by the enzymatic activity of the protein in the present invention. The modification in the present invention is involved preferably in autonomous transposition. The cell is preferably an animal cell, more preferably a vertebrate cell, and much more preferably fish cell including a zebrafish cell.

Genes containing the said gene to be transposed can be substances which do not exist in a natural cell, such as a plasmid carrying a foreign gene to be transposed, and also can be a genomic gene existing in a natural cell. In this case, cis-elements required for transposition could be added to the gene if necessary. The gene to be transposed is preferably a transposon, in certain circumstances, it may be a gene that insert a normal gene into the cell which has a disease caused by abnormalities of genes of various kinds.

Further, a method of modification in the present invention may only include the excision of part of a gene in a cell such as an inserted plasmid, however, may also include the insertion of all or part of the gene excised by this method, into any gene.

A gene excised in a method of modification in the present invention preferably has nucleotide sequences containing at least one inverted repeat in the forepart of its nucleotide

sequence. The inverted repeat is thought as a cis-element or part of cis-elements for transposition of the gene.

Further, the present invention, by using the said methods of modification, relates to a method of introducing a foreign gene into a gene of a cell and to a method of modifying a function of a cell based on expression of the gene. By performing the said methods, for example, it is possible for a foreign gene on a plasmid to be transposed into the genome in a cell, and for a new gene, which the cell concerned does not contain originally, to be inserted into a cell. Further, by expression of the newly inserted gene, it is possible to modify a function of a cell. Furthermore, the present invention can result in a cell, whose function has been modified by this method. The said cell is preferable as a cell described in this method.

As a plasmid in the present invention which contains the nucleotide sequence having at least one inverted repeat in the forepart of its nucleotide sequence, an optional substitute is to mediate transposition of a gene therein, contains a region containing at least one inverted repeat and a gene to be transposed near the repeat, and is easy to be inserted into a cell.

EXAMPLES

The present invention will be described by Examples below more precisely, but these Examples do not limit the present invention.

In the experiments in the present invention, eggs for injection were obtained from zebrafish strains, Tuebingen, TL and brass and were used for the following experiments.

Example 1

Cloning of cDNA

Zebrafish fertilized eggs were injected with the (Tol2-tyr) plasmid and, 9 hours after the injection, total RNA was extracted from 50 of zebrafish embryos with Tri Zol Reagent (Life Technologies, Inc.) and about 3 µg of the total RNA obtained was used for 3' RACE and 5' RACE, respectively.

Nested forward primers used to perform 3' RACE are:

To12f2;
5' - TTGGTCAGACATGTTTCATTG - 3' (SEQ ID NO:16)
and

To12f3;
5' - ATGTTTCATTGGTCTTTGGA - 3' , (SEQ ID NO:17)

To12f4;
5' - ATAGCTGAAGCTGCTCTGATC - 3' (SEQ ID NO:18)
and

To12f5;
5' - CTGCTCTGATC ATGAAACAG - 3' , (SEQ ID NO:19)

To12f8;
5' - GCTTAATAAAGAAATATCGGCC - 3' (SEQ ID NO:20)
and

To12f9;
5' - AATATCGGCCTTCAAAGTTTCG - 3' , (SEQ ID NO:21)
and

To12f12;
5' - CTGTAATCAGAGAGTGTATGTGTA - 3' (SEQ ID NO:22)
and

To12f13;
5' - ATTGTTACATTTATTGCATACAAT - 3' . (SEQ ID NO:23)

Nested reverse primers used for 5' RACE are:

To12r4; 5' - CTAATATGCTTCCTTAGG - 3' (SEQ ID NO:24)
and

To12r5; 5' - CTTCTTAGGTTTGATGGCG - 3' . (SEQ ID NO:25)

The 3' RACE and 5' RACE products were gel-extracted, cloned with TOPO TA Cloning Kit (Invitrogen, Inc.) and sequenced using the ABI PRISM 310 Genetic Analyzer.

The sequence determined is shown in SEQ ID NO:1 and the amino acid sequence of its translated region is shown in SEQ ID NO:2.

Also, the summary is shown in FIG. 1. The numbers in the parentheses are bp from the 5' end of the Tol2 element. DDBJ/EMBL/Genbank accession number for the cDNA sequence is AB032244.

Example 2

Construction of the (Tol2-tyr) Δin1ΔRV plasmid

The (Tol2-tyr)Δin1ΔRV plasmid was first constructed by replacing the NruI-NspV of the (Tol2-tyr) plasmid with the NruI-NspV fragment of the cDNA and the resulting plasmid was digested with EcoRV and self-ligated.

Example 3

mRNA Synthesis, Injection to Embryos and PCR Analysis

The cDNA encoding the entire coding region of the transposase was cloned in pBluescript SK+ (Stratagene), linearized, digested with proteinase K and phenol/chloroform extracted. mRNA was generated by in vitro transcription by using T7 RNA polymerase and the mCAP mRNA Capping kit (Stratagene). The concentration and the size of the transcript were examined on agarose gel electrophoresis.

Zebrafish fertilized eggs were injected with 1-2 nl of a DNA solution (~25 ng/µl of a plasmid DNA) with or without the mRNA (~5 ng/µl of the Tol2 mRNA) and incubated at 28° C. for ~8 hours. Each embryo was soaked in 50 µl of 10 mM EDTA, 10 mM Tris-HCl (pH8.0), 200 µg/ml proteinase K and incubated at 50° C. for 3 hours.

Then 1 µl of the lysed embryo was used for PCR (35 cycles of 94° C. 30 sec, 55° C. 30 sec and 72° C. 30 sec) using tyr-ex4f and tyr-ex5r primers (Kawakami et al., 1998). The PCR products were analyzed on 2% agarose gel electrophoresis. The result is shown in FIG. 4.

For the DNA sequencing analysis, the PCR products were gel-extracted, cloned with TOPO TA Cloning (Invitrogen) and sequenced. The presence of the injected plasmid DNA in each sample was verified by PCR (25 cycles of 94° C. 30 sec, 55° C. 30 sec and 72° C. 30 sec) using Tol2f1 (5'-TCCACCCATGCTTCCAGCAGTA-3', SEQ ID NO:28) and Tol2r3 (5'-CGTTGTGGTTGCAATCCATTCAAC-3', SEQ ID NO:29) primers.

INDUSTRIAL APPLICABILITY

The present invention results in a new protein having a transposase-like activity of a gene and the nucleic acid encoding the same.

Further, the present invention discloses that a transposase of a different family is able to generate an enzymatic activity which can catalyze transposition of a gene in a vertebrate cell, and greatly contributes to the development of technologies

concerning the transposition of a gene in vertebrate and the analyses of mutants generated by the said transposition. On the other hand however, since recent gene technologies are extending from modification of a cell to modification of an organism, a method of transposition of a gene in a cell in the present invention is expected not to be limited only to the

modification of a cell but also applicable to modification of the structures and functions of genes of mammals in the medical and agricultural fields as one of the methods for modifying the organism of the traits. It can be expected to be a powerful method especially for the gene therapy and the improvement of fish breeding.

 SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 29

<210> SEQ ID NO 1

<211> LENGTH: 2156

<212> TYPE: DNA

<213> ORGANISM: *Oryzias latipes*

<400> SEQUENCE: 1

```

acgtcatgtc acatctatta ccacaatgca cagcaccttg acctggaaat tagggaaatt      60
ataacagtca atcagtgga gaaatggag gaagtatgtg attcacagc agctgcgagc      120
agcacagtcc aaaatcagcc acaggatcaa gagcaccctg gcccgatatct tcgcgaattc      180
ttttctttaa gtgggtgtaaa taaagattca ttcaagatga aatgtgtcct ctgtctcccg      240
cttaataaag aaatatcggc cttcaaaagt tcgccatcaa acctaaggaa gcatattgag      300
agaatgcacc caaattacct caaaaaactac tctaaattga cagcacagaa gagaaagatc      360
gggacctcca cccatgcttc cagcagtaag caactgaaag ttgactcagt tttcccagtc      420
aaacatgtgt ctccagtcac tgtgaacaaa gctatattaa ggtacatcat tcaaggactt      480
catcctttca gcactgttga tctgccatca tttaagagc tgattagtag actgcagcct      540
ggcatttctg tcattacaag gcctacttta cgctccaaga tagctgaagc tgctctgac      600
atgaaacaga aagtgactgc tgccatgagt gaagttgaat ggattgcaac cacaacggat      660
tgttggactg cacgtagaaa gtcattcatt ggtgtaactg ctcaactggat caaccctgga      720
agtcttgaag gacattccgc tgcacttgcc tgcaaaagat taatgggctc tcatactttt      780
gaggactgag ccagtgccat gaatgatata cactcagagt atgaaatacg tgacaagggt      840
gtttgcacaa ccacagacag tggttccaac tttatgaagg ctttcagagt ttttgggtgtg      900
gaaaacaatg atatcgagac tgaggcaaga aggtgtgaaa gtgatgacac tgattctgaa      960
ggctgtggtg agggaagtga tgggtgtgaa ttccaagatg cctcacgagt cctggaccaa      1020
gacgatgget tcgaattcca gctacaaaaa catcaaaagt gtgcctgtca cttacttaac      1080
ctagtctcaa gcgttgatgc ccaaaaagct ctctcaaatg aacactaca gaaactctac      1140
agatctgtct ttggcaaatg ccaagcttta tggaataaaa gcagccgatc ggctctagca      1200
gctgaagctg ttgaatcaga aagccggctt cagcttttaa ggccaacca aacgcggtgg      1260
aattcaactt ttatggctgt tgacagaatt cttcaaattt gcaaagaagc aggagaaggc      1320
gcacttcgga atatatgac ctctcttgag gttccaatgt ttaatccagc agaaatgctg      1380
ttcttgacag agtgggocaa cacaatgcgt ccagttgcaa aagtactcga catcttgcaa      1440
gcggaacaga atacacagct ggggtggctg ctgcctagtg tccatcagtt aagcttgaaa      1500
cttcagcgac tccaccatcc tctcaggtac tgtgaccac ttgtggatgc cctacaacaa      1560
ggaatccaaa cacgattcaa gcatatgttt gaagatcctg agatcatagc agctgccatc      1620
cttctcccta aatttcggac ctcttgaca aatgatgaaa ccatcataaa acgaggcatg      1680
gactacatca gagtgcactc tgggcctttg gaccacaaga aggaattggc caacagttca      1740

```

-continued

tctgatgatg aagatTTTTT cgcttctttg aaaccgacaa cacatgaagc cagcaaagag 1800
 ttggatggat atctggcctg tgtttcagac accagggagt ctctgctcac gtttctctgct 1860
 atttgcagcc tctctatcaa gactaataca cctcttcccc catcggtctg ctgtgagagg 1920
 cttttcagca ctgcaggatt gcttttcagc cccaaaagag ctaggcttga cactaacaat 1980
 tttgagaatc agcttctact gaagttaaata ctgaggtttt acaactttga gtagcgtgta 2040
 ctggcattag attgtctgtc ttatagtttg ataattaat acaaacagtt ctaaagcagg 2100
 ataaaacctt gtatgcattt catttaatgt tttttgagat taaaagctta aacaag 2156

<210> SEQ ID NO 2
 <211> LENGTH: 649
 <212> TYPE: PRT
 <213> ORGANISM: *Oryzias latipes*

<400> SEQUENCE: 2

Met Glu Glu Val Cys Asp Ser Ser Ala Ala Ala Ser Ser Thr Val Gln
 1 5 10 15
 Asn Gln Pro Gln Asp Gln Glu His Pro Trp Pro Tyr Leu Arg Glu Phe
 20 25 30
 Phe Ser Leu Ser Gly Val Asn Lys Asp Ser Phe Lys Met Lys Cys Val
 35 40 45
 Leu Cys Leu Pro Leu Asn Lys Glu Ile Ser Ala Phe Lys Ser Ser Pro
 50 55 60
 Ser Asn Leu Arg Lys His Ile Glu Arg Met His Pro Asn Tyr Leu Lys
 65 70 75 80
 Asn Tyr Ser Lys Leu Thr Ala Gln Lys Arg Lys Ile Gly Thr Ser Thr
 85 90 95
 His Ala Ser Ser Ser Lys Gln Leu Lys Val Asp Ser Val Phe Pro Val
 100 105 110
 Lys His Val Ser Pro Val Thr Val Asn Lys Ala Ile Leu Arg Tyr Ile
 115 120 125
 Ile Gln Gly Leu His Pro Phe Ser Thr Val Asp Leu Pro Ser Phe Lys
 130 135 140
 Glu Leu Ile Ser Thr Leu Gln Pro Gly Ile Ser Val Ile Thr Arg Pro
 145 150 155 160
 Thr Leu Arg Ser Lys Ile Ala Glu Ala Ala Leu Ile Met Lys Gln Lys
 165 170 175
 Val Thr Ala Ala Met Ser Glu Val Glu Trp Ile Ala Thr Thr Thr Asp
 180 185 190
 Cys Trp Thr Ala Arg Arg Lys Ser Phe Ile Gly Val Thr Ala His Trp
 195 200 205
 Ile Asn Pro Gly Ser Leu Glu Arg His Ser Ala Ala Leu Ala Cys Lys
 210 215 220
 Arg Leu Met Gly Ser His Thr Phe Glu Val Leu Ala Ser Ala Met Asn
 225 230 235 240
 Asp Ile His Ser Glu Tyr Glu Ile Arg Asp Lys Val Val Cys Thr Thr
 245 250 255
 Thr Asp Ser Gly Ser Asn Phe Met Lys Ala Phe Arg Val Phe Gly Val
 260 265 270
 Glu Asn Asn Asp Ile Glu Thr Glu Ala Arg Arg Cys Glu Ser Asp Asp
 275 280 285
 Thr Asp Ser Glu Gly Cys Gly Glu Gly Ser Asp Gly Val Glu Phe Gln
 290 295 300

-continued

Asp Ala Ser Arg Val Leu Asp Gln Asp Asp Gly Phe Glu Phe Gln Leu
 305 310 315 320
 Pro Lys His Gln Lys Cys Ala Cys His Leu Leu Asn Leu Val Ser Ser
 325 330 335
 Val Asp Ala Gln Lys Ala Leu Ser Asn Glu His Tyr Lys Lys Leu Tyr
 340 345 350
 Arg Ser Val Phe Gly Lys Cys Gln Ala Leu Trp Asn Lys Ser Ser Arg
 355 360 365
 Ser Ala Leu Ala Ala Glu Ala Val Glu Ser Glu Ser Arg Leu Gln Leu
 370 375 380
 Leu Arg Pro Asn Gln Thr Arg Trp Asn Ser Thr Phe Met Ala Val Asp
 385 390 395 400
 Arg Ile Leu Gln Ile Cys Lys Glu Ala Gly Glu Gly Ala Leu Arg Asn
 405 410 415
 Ile Cys Thr Ser Leu Glu Val Pro Met Phe Asn Pro Ala Glu Met Leu
 420 425 430
 Phe Leu Thr Glu Trp Ala Asn Thr Met Arg Pro Val Ala Lys Val Leu
 435 440 445
 Asp Ile Leu Gln Ala Glu Thr Asn Thr Gln Leu Gly Trp Leu Leu Pro
 450 455 460
 Ser Val His Gln Leu Ser Leu Lys Leu Gln Arg Leu His His Ser Leu
 465 470 475 480
 Arg Tyr Cys Asp Pro Leu Val Asp Ala Leu Gln Gln Gly Ile Gln Thr
 485 490 495
 Arg Phe Lys His Met Phe Glu Asp Pro Glu Ile Ile Ala Ala Ala Ile
 500 505 510
 Leu Leu Pro Lys Phe Arg Thr Ser Trp Thr Asn Asp Glu Thr Ile Ile
 515 520 525
 Lys Arg Gly Met Asp Tyr Ile Arg Val His Leu Glu Pro Leu Asp His
 530 535 540
 Lys Lys Glu Leu Ala Asn Ser Ser Ser Asp Asp Glu Asp Phe Phe Ala
 545 550 555 560
 Ser Leu Lys Pro Thr Thr His Glu Ala Ser Lys Glu Leu Asp Gly Tyr
 565 570 575
 Leu Ala Cys Val Ser Asp Thr Arg Glu Ser Leu Leu Thr Phe Pro Ala
 580 585 590
 Ile Cys Ser Leu Ser Ile Lys Thr Asn Thr Pro Leu Pro Ala Ser Ala
 595 600 605
 Ala Cys Glu Arg Leu Phe Ser Thr Ala Gly Leu Leu Phe Ser Pro Lys
 610 615 620
 Arg Ala Arg Leu Asp Thr Asn Asn Phe Glu Asn Gln Leu Leu Leu Lys
 625 630 635 640
 Leu Asn Leu Arg Phe Tyr Asn Phe Glu
 645

<210> SEQ ID NO 3

<211> LENGTH: 196

<212> TYPE: PRT

<213> ORGANISM: Zea mays

<400> SEQUENCE: 3

Ile Asn Leu Ile Glu Pro Tyr Lys Tyr Asp Glu Val Val Ser Leu Lys
 1 5 10 15

Lys Leu His Leu Ala Ile Ile Met His Glu Tyr Pro Phe Asn Ile Val

-continued

20					25					30					
Glu	His	Glu	Tyr	Phe	Val	Glu	Phe	Val	Lys	Ser	Leu	Arg	Pro	His	Phe
		35						40					45		
Pro	Ile	Lys	Ser	Arg	Val	Thr	Ala	Arg	Lys	Tyr	Ile	Met	Asp	Leu	Tyr
		50						55				60			
Leu	Glu	Glu	Lys	Glu	Lys	Leu	Tyr	Gly	Lys	Leu	Lys	Asp	Val	Gln	Ser
		65			70					75					80
Arg	Phe	Ser	Thr	Thr	Met	Asp	Met	Trp	Thr	Ser	Cys	Gln	Asn	Lys	Ser
				85					90						95
Tyr	Met	Cys	Val	Thr	Ile	His	Trp	Ile	Asp	Asp	Asp	Trp	Cys	Leu	Gln
			100					105					110		
Lys	Arg	Ile	Val	Gly	Phe	Phe	His	Val	Glu	Gly	Arg	His	Thr	Gly	Gln
			115					120					125		
Arg	Leu	Ser	Gln	Thr	Phe	Thr	Ala	Ile	Met	Val	Lys	Trp	Asn	Ile	Glu
			130					135				140			
Lys	Lys	Leu	Phe	Ala	Leu	Ser	Leu	Asp	Asn	Ala	Ser	Ala	Asn	Glu	Val
					150					155					160
Ala	Val	His	Asp	Ile	Ile	Glu	Asp	Leu	Gln	Asp	Thr	Asp	Ser	Asn	Leu
				165					170						175
Val	Cys	Asp	Gly	Ala	Phe	Phe	His	Val	Arg	Cys	Ala	Cys	His	Ile	Leu
			180					185						190	
Asn	Leu	Val	Ala												
			195												

<210> SEQ ID NO 4
 <211> LENGTH: 14
 <212> TYPE: DNA
 <213> ORGANISM: *Oryzias latipes*
 <400> SEQUENCE: 4
 ggagttcttg accc 14

<210> SEQ ID NO 5
 <211> LENGTH: 14
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
 <400> SEQUENCE: 5
 ggagttcttg acag 14

<210> SEQ ID NO 6
 <211> LENGTH: 14
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
 <400> SEQUENCE: 6
 ctggttcttg accc 14

<210> SEQ ID NO 7
 <211> LENGTH: 14
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 7
ggagttcttg accc 14

<210> SEQ ID NO 8
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

<400> SEQUENCE: 8
ggagttcttc ttgacc 17

<210> SEQ ID NO 9
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

<400> SEQUENCE: 9
ggagttctct tgacc 16

<210> SEQ ID NO 10
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

<400> SEQUENCE: 10
gttttttttt tacatctcaa ctg 23

<210> SEQ ID NO 11
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

<400> SEQUENCE: 11
ctcaactgat agtctaataca cac 23

<210> SEQ ID NO 12
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

<400> SEQUENCE: 12
cgctgagctc tcttatatag aga 23

<210> SEQ ID NO 13
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

-continued

<400> SEQUENCE: 13

tatagagatg gctgttatac gag	23
---------------------------	----

<210> SEQ ID NO 14

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 14

aagtgcgctc aatgtgtttt cag	23
---------------------------	----

<210> SEQ ID NO 15

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 15

gttttcagct catctgttca tta	23
---------------------------	----

<210> SEQ ID NO 16

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 16

ttggtcagac atgttcattg	20
-----------------------	----

<210> SEQ ID NO 17

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 17

atgttcattg gtcctttgga	20
-----------------------	----

<210> SEQ ID NO 18

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 18

atagctgaag ctgctctgat c	21
-------------------------	----

<210> SEQ ID NO 19

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 19

-continued

ctgctctgat catgaaacag 20

<210> SEQ ID NO 20
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 20

gcttaataaa gaaatategg cc 22

<210> SEQ ID NO 21
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 21

aatatcgcc ttcaaaagtt cg 22

<210> SEQ ID NO 22
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 22

ctgtaatcag agagtgtatg tgta 24

<210> SEQ ID NO 23
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 23

attgttacat ttattgcata caat 24

<210> SEQ ID NO 24
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 24

ctcaaatatgc ttccttagg 19

<210> SEQ ID NO 25
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 25

-continued

```

cttccttagg ttgatggcg                               20

<210> SEQ ID NO 26
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 26

gctactacat ggtgccattc ct                             22

<210> SEQ ID NO 27
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 27

caatgccaga tctgctgggc tt                             22

<210> SEQ ID NO 28
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 28

tccaccatg cttccagcag ta                             22

<210> SEQ ID NO 29
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 29

cgttggtggt gcaatccatt caac                           24

```

What is claimed is:

1. A method of modifying a genome structure of a cell, the method comprising a) introducing a protein having the amino acid sequence of SEQ ID NO: 2, and a polynucleotide sequence comprising an exogenous nucleic acid and a cis-element of *Oryzias Latipes* Tol2 element into the cell, and b) modifying the genome structure by the insertion of the exogenous nucleic acid into the genome.

2. The method according to claim 1, wherein the cell is a vertebrate cell.

3. The method according to claim 1, wherein the exogenous nucleic acid and the cis-element of *Oryzias Latipes* Tol2 element are contained in a plasmid.

4. The method of claim 1, wherein the protein having the amino acid sequence of SEQ ID NO: 2 and the polynucleotide sequence of step a) are separately introduced into the cell.

5. The method of claim 1, wherein the protein having the amino acid sequence of SEQ ID NO: 2 and the polynucleotide sequence of step a) are simultaneously introduced into the cell.

* * * * *